Glysolin G Special Precautions

Insulin Glargine is not intended for IV administration. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycaemia.
Insulin Glargine is not the insulin of choice for the treatment of diabetic ketoacidosis. Instead, intravenous regular insulin is recommended in such cases.
Renal Impairment: In patients with renal impairment, insulin requirements may be diminished. In the elderly, progressive deterioration of renal function may lead to a steady decrease in insulin requirements.
Hepatic Impairment: In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Intercurrent conditions: Insulin requirements may be altered during intercurrent conditions such as illness, emotional disturbances or stress.
Effects on the Ability to Drive and Use Machines: The patient’s ability to concentrate and react may be impaired as a result of hypoglycemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).
Patients should therefore be advised to avoid hypoglycemia during driving. This is particularly significant in patients who have reduced awareness of the warning signs of hypoglycemia or have frequent episodes of hypoglycemia.
Use in Pregnancy & Lactation: To date, no relevant epidemiological data are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal or fetal development, parturition or postnatal development.
It is essential for parents with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy. Insulin requirements may decrease during the first trimester, increase during the second and third trimesters and rapidly decline after delivery. Careful blood glucose control is essential in such patients.